What's Happening?
Ascletis Pharma has announced that its GLP-1R/GIPR/GCGR triple peptide agonist, ASC37, demonstrated superior weight loss compared to tirzepatide in a diet-induced obese mouse model. ASC37 showed an 88% greater relative body weight reduction than tirzepatide.
The company plans to submit a biologics license application for both subcutaneous and oral formulations of ASC37 to the FDA, following the completion of Phase III trials.
Why It's Important?
ASC37's promising preclinical results suggest it could become a first-in-class treatment for severe obesity, offering a new option for weight management. The drug's classification as a biologic provides extended exclusivity and protection from price negotiations, potentially enhancing its market viability. This development aligns with Ascletis's strategy to leverage its proprietary technologies to address metabolic diseases, positioning the company as a leader in innovative obesity treatments.
What's Next?
Ascletis plans to submit an Investigational New Drug application for ASC37 in the third quarter of 2026, with biologics license applications to follow after Phase III completion. The company will continue to advance its pipeline of metabolic disease treatments, potentially expanding ASC37's indications. Successful regulatory approval could lead to commercialization and broader adoption of ASC37, impacting the obesity treatment landscape.
